中国合理用药探索2024,Vol.21Issue(2) :36-40.DOI:10.3969/j.issn.2096-3327.2024.02.006

骨科术后低分子肝素致血小板减少患者抗凝治疗的药学监护

Pharmaceutical Care for Anticoagulant Therapy in Patients with Heparin Induced Thrombocytopenia Following Orthopedic Surgery

王俪瓯 高增杰 邹弢 王宁 邱竹君 刘秀兰
中国合理用药探索2024,Vol.21Issue(2) :36-40.DOI:10.3969/j.issn.2096-3327.2024.02.006

骨科术后低分子肝素致血小板减少患者抗凝治疗的药学监护

Pharmaceutical Care for Anticoagulant Therapy in Patients with Heparin Induced Thrombocytopenia Following Orthopedic Surgery

王俪瓯 1高增杰 2邹弢 1王宁 1邱竹君 1刘秀兰1
扫码查看

作者信息

  • 1. 北京积水潭医院贵州医院药剂科,贵阳 550007
  • 2. 北京积水潭医院贵州医院骨外科,贵阳 550007
  • 折叠

摘要

目的:探讨临床药师为骨科术后使用低分子肝素过程中出现的肝素诱导的血小板减少症(HIT)患者和非HIT患者制定和实施个体化用药监护的过程.方法:临床药师通过排查患者用药相关性、查阅指南、检索文献资料等方法,分析讨论相关因素,协助医生制定和调整抗凝用药方案.结果:通过制定不同的血小板监测频率和实施个体化用药监护计划,患者的血小板计数逐渐恢复至正常值.结论:药物治疗过程中,临床药师应该警惕药品不良反应的发生,制定并实施个体化的药学监护,保障药物治疗过程中的安全性和有效性.

Abstract

Objective:To explore the process of developing and implementing individualized medication monitoring for patients with heparin induced thrombocytopenia(HIT)and those without HIT following orthopedic surgery.Methods:Clinical pharmacists assess the appropriateness of drug use in patients,consult reference guide,conduct literature search and employ other methods to analyze and discuss relevant factors,thereby assisting doctors in developing and adjusting anticoagulant programs.Results:The patients'platelet counts returned to normal through the development of different platelet monitoring frequencies and individualized medication monitoring.Conclusion:Clinical pharmacists should prioritize monitoring adverse drug reactions and implementing individualized medication monitoring to ensure the safety and effectiveness of drug therapy.

关键词

骨科术后/低分子肝素/血小板减少/药学监护/药品不良反应

Key words

orthopedic surgery/low molecular weight heparin/heparin induced thrombocytopenia/pharmaceutical care/adverse drug reaction

引用本文复制引用

基金项目

贵州省卫生健康委委科学技术基金(2021)(gzwkj2021-438)

出版年

2024
中国合理用药探索
中国执业药师协会

中国合理用药探索

影响因子:0.62
ISSN:2096-3327
参考文献量13
段落导航相关论文